FcγR Interaction Is Not Required for Effective Anti-Pd-L1 Immunotherapy but Can Add Additional Benefit Depending on the Tumor Model
International Journal of Cancer - United States
doi 10.1002/ijc.31899
Full Text
Open PDFAbstract
Available in full text
Date
November 12, 2018
Authors
Publisher
Wiley